Patient undergoing upper GI endoscopy comparing efficacy of Lidocaine Lozenges 200mg with Lidocaine spray 10%

Prospective comparative study of efficacy of Lidocaine Lozenges 200mg with Lidocaine spray 10% for pharyngeal anaesthesia during upper GI endoscopy - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089451

Enrollment

138

Registered

2025-06-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K210- Gastro-esophageal reflux disease with esophagitis

Interventions

Intervention1: Lidocaine Lozenges 200mg: Dose- Lidocaine Lozenges 200mg Route of Administration-ORAL Duration-10minutes prior to procedure Control Intervention1: Lidocaine Spray 10%: Dose-Lidocaine sp

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing upper gastrointestinal endoscopy All the adult patients ASA grade I and II Patients giving consent for study

Exclusion criteria

Exclusion criteria: H/O Anaphylaxis to Lignocaine K/C/O-Bleeding Tendencies Pregnant and Lactating females

Design outcomes

Primary

Measure	Time frame
Analgesic efficacy for level of gag reflexTimepoint: Analgesic efficacy for level of gag reflex	—

Secondary

Measure	Time frame
Incidence of any adverse evens and need for rescue medication and poatient global assesmentTimepoint: In 24hours	—

Countries

India

Contacts

Public ContactDr Surekha Shirish Patil

D Y Patil School of Medicine

surekha.patil@dypatil.edu9930923108

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026